RenovoRx (RNXT) Interest Expenses (2020 - 2026)
RenovoRx (RNXT) posted Interest Expenses of $13000.0 for Q1 2026, up 14672.73% sequentially from $88.0 in Q4 2025, and down 95.87% YoY from $315000.0 in Q1 2025.
RenovoRx (RNXT) Interest Expenses (2020 - 2026) Analysis & Trends
RenovoRx has reported Interest Expenses for 7 years, with the latest figure at $13000.0 in Q1 2026.
- Quarterly Interest Expenses fell 95.87% year-over-year to $13000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13000.0 (down 95.87% YoY) and the FY2025 annual result came in at $19.8 million, up 17.97% from the prior year.
- Interest Expenses advanced to $13000.0 in Q1 2026 per RNXT's latest filing, from $88.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $16.8 million in Q4 2024 and troughed at $88.0 in Q4 2025.
- A 5-year average of $1.6 million and a median of $717000.0 in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses surged 1670.46% in 2024, then tumbled 100.0% in 2025.
- Over 5 years, Interest Expenses stood at $928000.0 in 2022, then rose by 2.16% to $948000.0 in 2023, then soared by 1670.46% to $16.8 million in 2024, then sank by 100.0% to $88.0 in 2025, then jumped by 14672.73% to $13000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $13000.0, $88.0, and $861000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | RenovoRx | 61.96 Mn | 61.96 Mn | 766,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 425,000.00 |
| Jun 30, 2026 | 425,000.00 |
| Mar 31, 2026 | 13,000.00 |
| Mar 31, 2026 | 13,000.00 |
| Dec 31, 2025 | 88.00 |
| Dec 31, 2025 | 88.00 |
| Sep 30, 2025 | 861,000.00 |
| Sep 30, 2025 | 861,000.00 |
| Jun 30, 2025 | 989,000.00 |
| Jun 30, 2025 | 989,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Dec 31, 2024 | 16.78 Mn |
| Dec 31, 2024 | 16.78 Mn |
| Sep 30, 2024 | 195,000.00 |
| Sep 30, 2024 | 195,000.00 |
| Jun 30, 2024 | 290,000.00 |
| Jun 30, 2024 | 290,000.00 |
| Mar 31, 2024 | 547,000.00 |
| Mar 31, 2024 | 547,000.00 |